Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic treatments for high-risk localized prostate cancer.
Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-Schlurmann F, Loriot Y, Ploussard G, Sargos P, Timsit MO, Vincendeau S, Pasticier G, Borchiellini D. Pignot G, et al. Among authors: barthelemy p. Nat Rev Urol. 2018 Aug;15(8):498-510. doi: 10.1038/s41585-018-0017-x. Nat Rev Urol. 2018. PMID: 29765147 Review.
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
Beauval JB, Loriot Y, Hennequin C, Rozet F, Barthelemy P, Borchiellini D, Schlürmann Constans F, Gross E, Maillet D, Pasticier G, Pignot G, Timsit MO, Vincendeau S, Ploussard G, Sargos P. Beauval JB, et al. Among authors: barthelemy p. Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30. Crit Rev Oncol Hematol. 2018. PMID: 29458782 Review.
Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
Loriot Y, Supiot S, Beauval JB, Schlürmann F, Pasticier G, Sargos P, Barthélémy P, Pignot G, Maillet D, Vincendeau S, Gross E, Ploussard G, Timsit MO, Borchiellini D. Loriot Y, et al. Among authors: barthelemy p. Cancer Treat Rev. 2018 Nov;70:223-231. doi: 10.1016/j.ctrv.2018.09.006. Epub 2018 Sep 21. Cancer Treat Rev. 2018. PMID: 30300771 Review.
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F. Gravis G, et al. Among authors: barthelemy p. Cancer Treat Rev. 2017 Apr;55:211-217. doi: 10.1016/j.ctrv.2016.09.008. Epub 2016 Sep 10. Cancer Treat Rev. 2017. PMID: 27665366 Free article. Review.
Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Pignot G, Thiery-Vuillemin A, Albigès L, Walz J, Lang H, Balssa L, Parier B, Geoffrois L, Bensalah K, Schlürmann F, Ladoire S, Bigot P, Borchiellini D, Cassuto O, Thibault C, Ingels A, Saldana V, Roubaud G, Bernhard JC, Gravis G, Barthélémy P. Pignot G, et al. Among authors: barthelemy p. Eur Urol Oncol. 2022 Oct;5(5):577-584. doi: 10.1016/j.euo.2022.07.002. Epub 2022 Jul 17. Eur Urol Oncol. 2022. PMID: 35853818
Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C, Auclin E, Teyssonneau D, Laguerre B, Cancel M, Boughalem E, Noel J, Brachet PE, Maillet D, Barthelemy P, Helissey C, Thibault C, Oudard S. Pobel C, et al. Among authors: barthelemy p. Cancer Med. 2021 Sep;10(18):6304-6309. doi: 10.1002/cam4.4172. Epub 2021 Aug 12. Cancer Med. 2021. PMID: 34382352 Free PMC article.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Among authors: barthelemy p. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?
Pignot G, Thiery-Vuillemin A, Walz J, Lang H, Bigot P, Werle P, Balssa L, Geoffrois L, Leblanc L, Albigès L, di Nunno V, Bensalah K, Ladoire S, Gravis G, Barthélémy P. Pignot G, et al. Among authors: barthelemy p. Eur Urol. 2020 Jun;77(6):761-763. doi: 10.1016/j.eururo.2019.12.018. Epub 2020 Jan 3. Eur Urol. 2020. PMID: 31911011 No abstract available.
Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.
Guillaume Z, Colomba E, Thouvenin J, Saldana C, Campedel L, Dumont C, Laguerre B, Maillet D, Vicier C, Rolland F, Borchiellini D, Barthelemy P, Albiges L, Auclin E, Roulleaux Dugage M, Oudard S, Thibault C. Guillaume Z, et al. Among authors: barthelemy p. Cancers (Basel). 2022 Mar 25;14(7):1678. doi: 10.3390/cancers14071678. Cancers (Basel). 2022. PMID: 35406448 Free PMC article.
384 results